Bicalutamide with BCG for bladder cancer after BCG treatment
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial studies whether bicalutamide can improve outcomes for people with non-muscle-invasive bladder cancer who are starting BCG through the bladder. It may help prevent cancer from coming back or progressing after BCG.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man age 18 or older
- You have biopsy-proven non-muscle-invasive bladder cancer
- Your urologist has recommended starting BCG treatment through the bladder
- You received certain chemo instillations right after surgery (gemcitabine, epirubicin, or mitomycin C)
- If you have a partner who could become pregnant, you must use two reliable birth-control methods during the study and for at least 3 months after stopping the study drug
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if BCG therapy can prevent bladder cancer from coming back after surgery. It's for people with early-stage bladder cancer that hasn't spread into the muscle layer.
This trial compares two combinations of chemotherapy drugs given directly into the bladder to see which works better for patients whose bladder cancer has not responded to BCG therapy.
This trial tests a combination of chemotherapy placed directly into the bladder and an immunotherapy drug called pembrolizumab (given through a vein) for people with high-risk bladder cancer that has not completely responded to or has returned after BCG treatment.
This trial tests radiotherapy (high-energy X-rays) for a specific type of early-stage bladder cancer (CIS) that hasn't gone away after BCG treatment. It's for people who can't or choose not to have bladder removal surgery.
This trial tests whether bicalutamide can help men with non-muscle invasive bladder cancer (an early form that hasn’t spread into muscle). It is a Phase 1 study, meaning the main goal is to see how safe it is and learn how it behaves in the body for this cancer type.
This trial tests if a special type of tumor removal (ERBT) followed by BCG immunotherapy is better than standard treatment for medium- or high-risk non-muscle-invasive bladder cancer. It may help people whose bladder cancer has come back, has multiple tumors, or has a tumor larger than 1 cm.
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.